Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has issued an announcement.
Cinclus Pharma will release its first quarter report for 2025 on May 20, followed by a live presentation by CEO Christer Ahlberg and CFO Maria Engström. The report’s release and presentation are significant as they provide stakeholders with insights into the company’s financial health and progress, particularly concerning the development of linaprazan glurate, which addresses a significant need in the GERD treatment market.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and upper gastrointestinal tract disorders. Their leading drug candidate, linaprazan glurate, aims to treat gastroesophageal reflux disease (GERD) more effectively than current treatments, with phase III studies planned for 2025.
Average Trading Volume: 67,902
Learn more about CINPHA stock on TipRanks’ Stock Analysis page.